8th DDR Inhibitors Summit 2025
When:
Tuesday, Jan 28, 2025 8:30a -
Thursday, Jan 30, 2025 5:00p
Tuesday, Jan 28, 2025 8:30a -
Thursday, Jan 30, 2025 5:00p
Where:
Hilton Boston Back Bay
40 Dalton Street
Boston, Massachusetts 02115
Admission:
$2599.00 - $5097.00
Hosted by:
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/2658144-0?pid=5248
Making Strides in Targeting PARP, ATR, ATM, WEE1 and POLθ
AstraZeneca and Merck are at the forefront of DDR inhibitor development, focusing on next-generation PARP inhibitors and innovative combination therapies. At the same time, Roche and Novartis are pushing their own DDR-targeting pipelines, exploring emerging targets such as USP1 and WRN - these combined efforts are making DDR inhibitor drug development an increasingly dynamic and transformative area.
Additionally, biotechs like Artios Pharma and Repare Therapeutics are expanding the field with cutting-edge research and clinical programs, using innovative platforms to understand cancer biology, discover novel DDR targets, and identify patients most likely to benefit from the treatments.
In light of these advancements, the 8th Annual DDR Inhibitors Summit, returning to Boston this January, is the community hotspot for biopharma drug developers and researchers to collaborate on advancing DDR therapeutics.
Join 100+ experts from discovery, preclinical, translational, regulatory, and clinical roles as they unite to harness the potential of DDR inhibitors for cancer treatment and enhance patient outcomes.
What's New for 2025?
- Hear From Leading Voices: Insight from industry leaders such as Lisa Mahnke (President, Board Member, Chief Executive and Medical Officer, Nerviano Medical Sciences), Harry Raftopoulos (Senior Vice President, Clinical Research, Head of Oncology, Eikon Therapeutics), and Kirk Tanner (Chief Scientific Officer, National Brain Tumor Society) sharing their experiences in advancing DDR therapeutics
- Evaluate Novel DDR Pathways: Presentations on innovative approaches like Eisbach Bio's first-in-class allosteric inhibitor of ALC1, ForX Therapeutics' potent PARG inhibitor, and CTX-439, and Chordia Therapeutics' first-in-class CDK12 inhibitor, highlighting their potential in clinical applications
- Explore Innovative Drug Discovery and Development: Insights on AI-powered methodologies for identifying synthetic lethal DDR targets from Insilico Medicine and assessing the patient-selection capabilities of of Allarity Therapeutic's Drug Response Predictor (DRP) diagnostic
URLs:
Tickets: https://go.evvnt.com/2658144-2?pid=5248
Brochure: https://go.evvnt.com/2658144-3?pid=5248
Category: Conferences | Health
Prices:
Drug Developer Pricing - Conference + Biomarker-Focused Pre-Conference Day: USD 4197.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + Biomarker-Focused Pre-Conference Day: USD 3597.00,
Academic Pricing - Conference: USD 2599.00,
Solution Provider Pricing - Conference + Biomarker-Focused Pre-Conference Day: USD 5097.00,
Solution Provider Pricing - Conference Only: USD 3699.00
Speakers: David Proia, Vice President of Biology and Drug Discovery, Acrivon Therapeutics, Thomas Jensen, Chief Executive Officer, Allarity Therapeutics, Vera Grinkevich, Associate Director and Principal Scientist, Artios Pharma, Jian Wang, Executive Director, Global Head of Translational, Oncology Regulatory Science, Strategy and Excellence, AstraZeneca, Mark O'Connor, Chief Scientist, Oncology R and D, Head of the DNA Damage Response Strategic Biology Area, AstraZeneca, Dasha Kaloujskaia, Research Analyst, Beacon, Frederick Derheimer, Senior Director, Drug Discovery Biology, Boundless Bio, Konstantin Taganov, Vice President, Discovery, Blacksmith Medicines, Daisuke Morishita, Co-Founder and Chief Scientific Officer, Chordia Therapeutics, Kalindi Parmar, Associate Director, Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Andreas Ladurner,Chief Scientific Officer, Co-Founder and CoManaging Director, Eisbach Bio, Harry Raftopoulos, Senior Vice President and Head of Clinical Research and Oncology, Eikon Therapeutics, Jatinder Mukker, Director, Quantitative Pharmacology, EMD Serono, Alfie Brennan, Chief Scientific Officer, Evariste, Frank Zenke, Chief Scientific Officer, FoRx Therapeutics, Keith Mikule, Vice President, Business Development, InSilico Medicine, Jann Sarkaria, Professor of Radiation Oncology, Mayo Clinic, Robert Mutter, Associate Professor, Department of Radiation Oncology, Mayo Clinic, Timothy Yap, Head of Clinical Development, Vice President, Therapeutics Discovery Division, MD Anderson Cancer Center, Kirk Tanner, Chief Scientific Officer, National Brain Tumor Society, Lisa Mahnke, President, Board Member, Chief Executive and Medical Officer, Nerviano Medical Sciences, Wendy Fantl, Director and Head, Systems-Level Translational Discovery, Discovery Sciences, Biomedical Research, Novartis, Elia Aguado-Fraile, Associate Director, Translational Science, Repare Therapeutics, Hiroki Umehara, Senior Director, Sumitomo Pharma, Steph LaHaye, Principal Scientist, Translational Research, Tempus, Sharon Cantor, Professor, University of Massachusetts Medical School, David Mankoff, Professor and Research Vice-Chair of Radiology, Scientific Advisory Board Member and Cofounder, University of Pennsylvania and Trevarx Biomedical, Eric J. Brown, Associate Professor and Scientific Consultant, University of Pennsylvania and Aprea Therapeutics, Wei Zhong, Chief Executive Officer, Wayshine Pharma, Ranjit Bindra, Professor, Director, Brain Tumor Center, Yale University, Jianhui Ma, Associate Director, Zentalis Pharmaceuticals
